Chest CT features of the novel coronavirus disease (COVID-19)

FURKAN UFUK
RECEP SAVAŞ

Follow this and additional works at: https://journals.tubitak.gov.tr/medical

Part of the Medical Sciences Commons

Recommended Citation
UFUK, FURKAN and SAVAŞ, RECEP (2020) "Chest CT features of the novel coronavirus disease (COVID-19)," Turkish Journal of Medical Sciences: Vol. 50: No. 4, Article 2. https://doi.org/10.3906/sag-2004-331
Available at: https://journals.tubitak.gov.tr/medical/vol50/iss4/2

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.
1. Introduction

Since December 2019, a novel bat-origin coronavirus (2019-nCoV), also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), capable of infecting humans has been identified, and the disease caused by this virus was officially named as COVID-19 by the World Health Organization [1]. Until April 27, 2020, there were 2,804,796 confirmed cases with COVID-19 and 193,710 COVID-19 related deaths [2]. COVID-19 is a rapidly spreading viral disease and can cause serious health problems, especially pneumonia, necrotizing encephalopathy, systemic and pulmonary thromboembolism, acute respiratory distress syndrome (ARDS), respiratory failure, systemic inflammatory response, and sepsis [1,3–5]. Therefore, professional consensus, guidelines, and criteria have been published continuously to facilitate the diagnosis, management, follow-up, and isolation of patients [6–8].

Although the reverse transcription-polymerase chain reaction (RT-PCR) test is the gold standard for the diagnosis of COVID-19, chest x-ray and computed tomography (CT) have an essential role in the diagnosis of viral pneumonia, monitoring disease progression, determination of disease severity, and evaluating therapeutic efficacy. Chest CT can show important clues of 2019-nCoV disease (also known as COVID-19) in patients with an appropriate clinic. Prompt diagnosis of COVID-19 is essential to prevent disease transmission and provides close clinical observation of patients with clinically severe disease. Therefore, radiologists and clinicians should be familiar with the CT imaging findings of COVID-19 pneumonia. Herein, we aimed to review the imaging findings of COVID-19 pneumonia and examine the critical points to be considered for imaging in cases with COVID-19 suspicion.

2. Usual imaging findings

The reported prevalence of the common CT findings is shown in Table 1.

2.1. Ground glass opacity

Ground glass opacity (GGO) is an increase in lung density without obscuring vascular margins in the
## Table 1. The reported prevalence of the usual computed tomography findings.

| Publication | Number of patients | Study Origin | GGO | GGO with consolidation | Consolidation | Airway changes | PVE | Air bronchogram | Crazy paving pattern | Reticular and/or linear pattern |
|-------------|--------------------|--------------|-----|------------------------|--------------|----------------|-----|----------------|----------------------|--------------------------------|
| Xie et al. [9] | 5                  | China        | 5 (100%) | 2 (40%) | - | - | - | - | - | - |
| Fang et al. [10] | 51                 | China        | 36 (72%) | 30 (59%) | 0 | 4 (19%) | - | - | - | - |
| Chung et al. [11] | 21                 | China        | 12 (57%) | 6 (29%) | 0 | 4 (19%) | - | - | - | - |
| Wu et al. [12] | 121                | U.S.A.       | 39 (34%) | 50 (41%) | 28 (23%) | 2 (2%) | 6 (5%) | 33 (85%) | 16 (13%) | 35 (45%) |
| Wu et al. [13] | 80                 | China        | 73 (91%) | - | 50 (63%) | 23 (29%) | 38 (47%) | 9 (11%) | - | - |
| Song et al. [14] | 51                 | China        | 39 (77%) | 30 (59%) | 28 (55%) | 12 (19%) | 4 (19%) | - | - | 11 (22%) |
| Pan et al. [15] | 63                 | China        | 54 (85.7%) | - | 12 (19.0%) | - | - | - | - | 11 (17.5%) |
| Ng et al. [16] | 21                 | China        | 18 (86%) | - | 13 (62%) | - | - | - | - | - |
| Pan et al. [17] | 21                 | China        | 15 (71%) | 6 (29%) | 0 | 4 (19%) | - | - | - | - |
| Han et al. [18] | 108                | China        | 65 (60%) | 44 (41%) | 24 (21%) | 2 (2%) | 6 (5%) | 16 (13%) | 8 (7%) | - |
| Xu et al. [19] | 90                 | China        | 65 (72%) | - | 12 (13%) | 7 (8%) | - | - | - | - |
| Zhao et al. [20] | 101                | China        | 87 (86.1%) | 63 (64.4%) | 44 (42.6%) | 21 (33.9%) | 39 (62.9%) | 45 (72.2%) | 20 (32.2%) | 28 (45.2%) |
| Wu et al. [21] | 80                 | China        | 73 (91%) | - | 50 (63%) | 23 (29%) | 38 (47%) | 9 (11%) | - | - |
| Song et al. [22] | 51                 | China        | 39 (77%) | 30 (59%) | 28 (55%) | 12 (19%) | 4 (19%) | - | - | 11 (22%) |
| Pan et al. [23] | 63                 | China        | 54 (85.7%) | - | 12 (19.0%) | - | - | - | - | 11 (17.5%) |
| Ng et al. [24] | 21                 | China        | 18 (86%) | - | 13 (62%) | - | - | - | - | - |
| Pan et al. [25] | 21                 | China        | 15 (71%) | 6 (29%) | 0 | 4 (19%) | - | - | - | - |
| Han et al. [26] | 108                | China        | 65 (60%) | 44 (41%) | 24 (21%) | 2 (2%) | 6 (5%) | 16 (13%) | 8 (7%) | - |
| Xu et al. [27] | 90                 | China        | 65 (72%) | - | 12 (13%) | 7 (8%) | - | - | - | - |
| Zhao et al. [28] | 101                | China        | 87 (86.1%) | 63 (64.4%) | 44 (42.6%) | 21 (33.9%) | 39 (62.9%) | 45 (72.2%) | 20 (32.2%) | 28 (45.2%) |
| Wu et al. [29] | 80                 | China        | 73 (91%) | - | 50 (63%) | 23 (29%) | 38 (47%) | 9 (11%) | - | - |
| Song et al. [30] | 51                 | China        | 46 (90.2%) | 28 (54.9) | 3 (5.9) | 36 (70.6) | 35 (68.6) | 86 (80%) | - | - |
| Pan et al. [31] | 63                 | China        | 25 (40.3%) | - | 21 (33.9%) | 39 (62.9%) | 43 (40%) | 52 (48%) | - | - |
| Xu et al. [32] | 41                 | China        | 30 (73%) | 25 (61%) | 15 (37%) | 33 (80%) | 22 (54%) | - | - | - |
| Li et al. [33] | 51                 | China        | 46 (90.2%) | 28 (54.9) | 3 (5.9) | 36 (70.6) | 35 (68.6) | 86 (80%) | - | - |
| Yang et al. [34] | 149                | China        | 409 (46%) | 447 (50%) | - | - | - | 44 (54.8%) | 54 (65.1%) | 8 (1%) |
| Li et al. [35] | 83                 | China        | 81 (97.6%) | - | 53 (63.9%) | 30 (36.1%) | 19 (22.9%) | - | - | - |
| Xiong et al. [36] | 42                | China        | 42 (100%) | - | 23 (55%) | - | - | - | - | 15 (36%) |
| Bai et al. [37] | 219                | China        | 200 (91%) | 141 (64%) | 11 (50%) | 8 (14%) | 3 (27%) | 26 (17.4%) | 10 (13.6) | 79 (53.8%) |
| Cheng et al. [38] | 11                | U.S.A.       | 11 (100%) | 7 (65.6) | 6 (54.5) | 14 (17%) | 8 (10%) | 34 (31%) | - | - |
| Shi et al. [39] | 81                 | China        | 53 (63.9%) | - | 14 (13%) | - | - | - | - | 33 (41.1%) |
| Wang et al. [40] | 93                | China        | 69 (72.2%) | - | 28 (31.6%) | - | - | - | - | 15 (16.1) |
| Fan et al. [41] | 110                | China        | 69 (72.2%) | - | 28 (31.6%) | - | - | - | - | 15 (16.1) |
| Guan et al. [42] | 129                | China        | 82 (35.3%) | - | 14 (12%) | - | - | - | - | 33 (41.1%) |
| Zhang et al. [43] | 123                | China        | 45 (80.4%) | - | 12 (21.4%) | 25 (44.6%) | 41 (73.2%) | - | - | - |
| Zhu et al. [44] | 88                | China        | 45 (80.4%) | - | 12 (21.4%) | 25 (44.6%) | 41 (73.2%) | - | - | - |
| Liu et al. [45] | 67                | China        | 45 (70.5%) | - | 30 (46%) | - | - | - | - | 19 (28.5%) |

GGO: ground-glass opacity; PVE: pulmonary vascular enlargement.
Ground glass opacities with a peripheral and multi-lobar distribution is a common finding in COVID-19 patients, and GGO is usually more prominent in lower-middle lobes and posterior lung areas (Figures 1a and 1b). The reported prevalence of GGO varies between 46% and 100%, and GGO has usually been seen in the early phases of the disease and/or mild pulmonary infection [9–11,13,14,18–43]. As the disease stage and severity increase, usually consolidation and/or interstitial thickening (crazy paving pattern) begins to appear within the GGO areas. Besides, while GGO or consolidation are healing, it can be seen as a GGO containing fibrotic band or atelectasis in the lung [31].

2.2. Consolidation
Pulmonary consolidation is defined as an increase in lung density with obscuring vascular margins in the lung parenchyma due to the complete replacement of air spaces (alveolus and alveolar sacs) by fluid, pus, blood, or cells [17]. Peripheral, segmental, or sub-segmental consolidation areas with the multi-lobar distribution are usually seen in cases with COVID-19 pneumonia, especially in older patients and patients with severe or critical disease (Figure 2) [11,14–16,31,39]. Consolidation areas are usually seen in mixed patterns with GGO, and the new emergence of consolidation areas in the follow-up imaging of COVID-19 patients was considered as an indicator of progressive disease [11]. Besides, consolidative lesions have been reported in COVID-19 patients with a longer time interval between onset of symptoms and chest CT scan, or patients over 50 years of age [31,39].

The prevalence of thromboembolic events in patients with COVID-19 has been shown to increase compared to the healthy population. Therefore, when CT shows peripherally located, triangular-shaped consolidation areas, pulmonary thromboembolism, and infarction (Hampton hump) should be considered in the differential diagnosis [44,45].

2.3. Crazy paving pattern
The crazy paving pattern indicates a ground-glass opacity (GGO) with superimposed interlobular septal thickening and prominent intralobular lines [14,17]. Crazy paving pattern opacities are not uncommon in COVID-19 patients, and the reported prevalence of crazy paving pattern varies between 5% and 89% [9–11,13,14,18–43] (Figures 1a and 1b) (Table 1). Crazy paving pattern may indicate interstitial inflammation and alveolar damage in patients with COVID-19, which had been previously reported in patients with Middle East Respiratory Syndrome (MERS) and the Severe Acute Respiratory Syndrome (SARS) [46]. In the follow-up, the increase in the density of GGO and the emergence of opacities with the crazy paving pattern was demonstrated in the early stage of COVID-19 pneumonia. Moreover, the progression of the crazy paving pattern to consolidation and the emergence of pleural effusion have been reported in the late stage of COVID-19 pneumonia [8,19,31].

2.4. Air bronchogram and airway changes
Air bronchogram is the appearance of air-filled and low attenuated bronchi on a background of the high attenuated opaque lung, and the air bronchogram has almost always been caused by airspace pathology [17]. Air bronchogram sign has been frequently reported in cases with COVID-19.

![Figure 1. a) A 48-year-old man with COVID-19 presented with cough, fever, myalgia, and malaise for 3 days. Axial chest CT image shows multifocal, peripheral-peribronchovascular ground-glass opacities (red frames). b) The magnified image of the right lower lobe shows ground-glass opacity superimposed with interlobular septal thickening and prominent intralobular lines (red arrowheads), which indicates a crazy-paving pattern.](image-url)
pneumonia (Figures 3a and 3b). Song et al. [18] have been reported that 80% (n = 41/51) of patients with COVID-19 pneumonia had air bronchograms. Besides, COVID-19 patients may have airway changes such as endobronchial mucus plugging, bronchiectasis, bronchioleactasis, and bronchial wall thickening [9–11,13,14,18–43] (Table 1). Moreover, the prevalence of bronchial wall thickening in COVID-19 patients with severe-critical clinical features has been shown to be significantly higher than in patients with mild-common clinical features [14,41].

2.5. Pulmonary vascular enlargement
Pulmonary vascular enlargement (PVE), also known as pulmonary vascular widening, is defined as the widening of the subsegmental pulmonary vessel (pulmonary arteries and veins) with a diameter of more than 3 mm around and/or inside the opacity on CT (Figures 4a and 4b) [24,25,27,32,35,39]. Although the pathophysiology of PVE is not fully understood, PVE plays a potential diagnostic role for COVID-19. Bai and colleagues [32] had compared the CT findings in patients with COVID-19 pneumonia and non-COVID-19 pneumonia, and they found that the PVE was significantly associated with COVID-19 (P < 0.001, 59% vs. 22%). Moreover, PVE was reported in 45.2% to 89.2% of COVID-19 patients [24,25,27,32,35,39] (Table 1). PVE can be attributed to the vascular wall inflammatory infiltration [24,32,35].

2.6. Reticular pattern and linear opacification
The reticular pattern is the pathological process of the pulmonary interstitium and characterized by interlobular septal thickening and prominent intralobular lines [17]. The reticular pattern is usually seen in COVID-19 patients with pneumonia and reticulation may increase in patients with longer disease course [8,19,31]. The reported prevalence of reticular pattern and linear opacification
is very variable in the literature and has been reported between 1% and 81% [13,14,18,19,23–41]. Moreover, subpleural curvilinear lines and fibrous stripes have been reported in COVID-19 patients (Figures 5a and 5b) [14,18–43], and both may represent the replacement of cellular components by fibrosis [14,19]. It has been shown that cured patients with COVID-19 pneumonia may have persistent reticular opacities on CT [31].

2.7. Pulmonary embolism
Life-threatening thromboembolic events are increasingly identified in COVID-19 patients [44,45,47]. Recently, Grillet and colleagues [44] reported the prevalence of pulmonary embolism (PE) as 23% (n = 23/100) in COVID-19 patients with severe clinical features, and they reported that COVID-19 patients with PE, had a higher requirement for mechanical ventilation than those

Figure 3. A 33-year-old woman with COVID-19 presented with cough, fever, and pleuritic chest pain for 2 days. Axial chest CT image shows a focal consolidation with air bronchogram sign in the right lower lobe (a, red arrows). The sagittal reconstructed CT image of the right lower lobe shows air bronchogram sign inside the consolidation (b, red arrow).

Figure 4. A 46-year-old woman with COVID-19. Axial chest CT image shows peripheral and peribronchovascular distributed focal ground-glass opacities in both lungs, and focal vascular enlargement is seen inside the ground-glass opacity in the right lower lobe (a, red frame). The magnified image of the red frame shows vascular enlargement inside the ground-glass opacity (b, arrows).
Moreover, Leonard-Lorant et al. [47] reported that 22 of 106 patients (30%) with COVID-19 had acute pulmonary thromboembolism. Elevated D-dimer levels have been frequently reported in COVID-19 cases, especially in COVID-19 patients with PE [5,45,47]. Current guidelines recommend performing unenhanced chest CT for COVID-19 suspected patients with risk factors and/or severe-critical clinical findings. However, thromboembolic events associated with COVID-19 infection are not uncommon. Besides, especially those treated in the intensive care unit and patients in mechanical ventilation therapy are in the high-risk group for deep venous thrombosis and PE [44,45]. Therefore, pulmonary CT angiography is essential for evaluating lung parenchyma and vascular complications for COVID-19 cases with severe and/or critical clinical features and high D-dimer levels (Figures 6a, 6b, and 6c). Recently, the British Thoracic Imaging Association has suggested that if pulmonary CT angiography (CTA) is required in a potential COVID-19 patient, prior to CTA, an unenhanced chest CT should be performed because mosaic attenuation in CTA can be confused with GGO [48].

3. Unusual imaging findings
The reported prevalence of the unusual CT findings is shown in Table 2.

3.1. Pleural thickening and effusion
Pleural pathologies such as pleural effusion and focal pleural thickening have been rarely reported in cases with COVID-19, and pleural pathologies are usually seen in the later stages of the disease [21,31,39]. The presence of pleural effusion is thought to be a sign of poor prognosis in COVID-19 pneumonia, and the prevalence of pleural effusion in COVID-19 patients has been reported to range from 0% to 20% [11,13,14,18–43] (Table 2). Besides, the pleural effusion and thickening might be associated with dense pleural inflammation in patients with COVID-19 (Figures 6a, 6b, 6c, 7a, 7b) [24].

3.2. Air bubble sign
The air bubble sign has been defined as a small air-containing space that may be a pathological enlargement of bronchioles inside the opacity [25,28]. Air bubble sign is named in the literature under different names (cystic air space, round cystic changes, air-containing space, sieve-hole sign, and vacuolar sign). Although its pathophysiology is unclear, it may be related to the pathological expansion of alveolar sacs or bronchioles or the absorption process of consolidation, and the reported prevalence of air bubble sign in patients with COVID-19 pneumonia ranges from 8.1% to 54.8% (Figure 8) [25,28,33,34,35,39] (Table 2).

3.3. Nodules
A nodule refers to opacity in the lung parenchyma, less than or equal to 3 cm in diameter [17]. Shi and colleagues [34] reported that lung nodules were detected in 6% of patients with COVID-19 pneumonia. Similarly, Li and colleagues [30] reported that pulmonary nodules with or without visible halo sign were detected in 7.2% of patients with COVID-19 pneumonia (Figure 9). The halo sign indicates GGO surrounding a pulmonary nodule or mass and usually seen in patients with invasive fungal infections, hypervascular pulmonary metastases, and organizing pneumonia [17]. Although it is reported in the literature without PE. Moreover, Leonard-Lorant et al. [47] reported that 22 of 106 patients (30%) with COVID-19 had acute pulmonary thromboembolism. Elevated D-dimer levels have been frequently reported in COVID-19 cases, especially in COVID-19 patients with PE [5,45,47]. Current guidelines recommend performing unenhanced chest CT for COVID-19 suspected patients with risk factors and/or severe-critical clinical findings. However, thromboembolic events associated with COVID-19 infection are not uncommon. Besides, especially those treated in the intensive care unit and patients in mechanical ventilation therapy are in the high-risk group for deep venous thrombosis and PE [44,45]. Therefore, pulmonary CT angiography is essential for evaluating lung parenchyma and vascular complications for COVID-19 cases with severe and/or critical clinical features and high D-dimer levels (Figures 6a, 6b, and 6c). Recently, the British Thoracic Imaging Association has suggested that if pulmonary CT angiography (CTA) is required in a potential COVID-19 patient, prior to CTA, an unenhanced chest CT should be performed because mosaic attenuation in CTA can be confused with GGO [48].

3. Unusual imaging findings
The reported prevalence of the unusual CT findings is shown in Table 2.

3.1. Pleural thickening and effusion
Pleural pathologies such as pleural effusion and focal pleural thickening have been rarely reported in cases with COVID-19, and pleural pathologies are usually seen in the later stages of the disease [21,31,39]. The presence of pleural effusion is thought to be a sign of poor prognosis in COVID-19 pneumonia, and the prevalence of pleural effusion in COVID-19 patients has been reported to range from 0% to 20% [11,13,14,18–43] (Table 2). Besides, the pleural effusion and thickening might be associated with dense pleural inflammation in patients with COVID-19 (Figures 6a, 6b, 6c, 7a, 7b) [24].

3.2. Air bubble sign
The air bubble sign has been defined as a small air-containing space that may be a pathological enlargement of bronchioles inside the opacity [25,28]. Air bubble sign is named in the literature under different names (cystic air space, round cystic changes, air-containing space, sieve-hole sign, and vacuolar sign). Although its pathophysiology is unclear, it may be related to the pathological expansion of alveolar sacs or bronchioles or the absorption process of consolidation, and the reported prevalence of air bubble sign in patients with COVID-19 pneumonia ranges from 8.1% to 54.8% (Figure 8) [25,28,33,34,35,39] (Table 2).

3.3. Nodules
A nodule refers to opacity in the lung parenchyma, less than or equal to 3 cm in diameter [17]. Shi and colleagues [34] reported that lung nodules were detected in 6% of patients with COVID-19 pneumonia. Similarly, Li and colleagues [30] reported that pulmonary nodules with or without visible halo sign were detected in 7.2% of patients with COVID-19 pneumonia (Figure 9). The halo sign indicates GGO surrounding a pulmonary nodule or mass and usually seen in patients with invasive fungal infections, hypervascular pulmonary metastases, and organizing pneumonia [17]. Although it is reported in the literature without PE. Moreover, Leonard-Lorant et al. [47] reported that 22 of 106 patients (30%) with COVID-19 had acute pulmonary thromboembolism. Elevated D-dimer levels have been frequently reported in COVID-19 cases, especially in COVID-19 patients with PE [5,45,47]. Current guidelines recommend performing unenhanced chest CT for COVID-19 suspected patients with risk factors and/or severe-critical clinical findings. However, thromboembolic events associated with COVID-19 infection are not uncommon. Besides, especially those treated in the intensive care unit and patients in mechanical ventilation therapy are in the high-risk group for deep venous thrombosis and PE [44,45]. Therefore, pulmonary CT angiography is essential for evaluating lung parenchyma and vascular complications for COVID-19 cases with severe and/or critical clinical features and high D-dimer levels (Figures 6a, 6b, and 6c). Recently, the British Thoracic Imaging Association has suggested that if pulmonary CT angiography (CTA) is required in a potential COVID-19 patient, prior to CTA, an unenhanced chest CT should be performed because mosaic attenuation in CTA can be confused with GGO [48].

3. Unusual imaging findings
The reported prevalence of the unusual CT findings is shown in Table 2.

3.1. Pleural thickening and effusion
Pleural pathologies such as pleural effusion and focal pleural thickening have been rarely reported in cases with COVID-19, and pleural pathologies are usually seen in the later stages of the disease [21,31,39]. The presence of pleural effusion is thought to be a sign of poor prognosis in COVID-19 pneumonia, and the prevalence of pleural effusion in COVID-19 patients has been reported to range from 0% to 20% [11,13,14,18–43] (Table 2). Besides, the pleural effusion and thickening might be associated with dense pleural inflammation in patients with COVID-19 (Figures 6a, 6b, 6c, 7a, 7b) [24].

3.2. Air bubble sign
The air bubble sign has been defined as a small air-containing space that may be a pathological enlargement of bronchioles inside the opacity [25,28]. Air bubble sign is named in the literature under different names (cystic air space, round cystic changes, air-containing space, sieve-hole sign, and vacuolar sign). Although its pathophysiology is unclear, it may be related to the pathological expansion of alveolar sacs or bronchioles or the absorption process of consolidation, and the reported prevalence of air bubble sign in patients with COVID-19 pneumonia ranges from 8.1% to 54.8% (Figure 8) [25,28,33,34,35,39] (Table 2).

3.3. Nodules
A nodule refers to opacity in the lung parenchyma, less than or equal to 3 cm in diameter [17]. Shi and colleagues [34] reported that lung nodules were detected in 6% of patients with COVID-19 pneumonia. Similarly, Li and colleagues [30] reported that pulmonary nodules with or without visible halo sign were detected in 7.2% of patients with COVID-19 pneumonia (Figure 9). The halo sign indicates GGO surrounding a pulmonary nodule or mass and usually seen in patients with invasive fungal infections, hypervascular pulmonary metastases, and organizing pneumonia [17]. Although it is reported in the literature
that tree-in-bud pattern nodules can be seen in patients with COVID-19 [24,28, 33,35], superimposed bacterial infections or aspiration should be considered first when these nodules are detected.

3.4. Reversed halo sign
The reversed halo sign (RHS) indicates a central GGO surrounded by denser ring-like (crescentic shape) consolidation and also known as the Atoll sign [17]. Although RHS is usually seen in patients with cryptogenic organized pneumonia (COP), it has been reported in several cases with COVID-19 [13,20,27,32,35]. While Bernheim et al. [13] reported that the reversed halo sign was detected in 2 of 121 patients (1.7%) with COVID-19 pneumonia, Wang et al. [35] reported the prevalence of reversed halo sign as 15.1% (14 of 93 patients) (Table 2) (Figure 10).

3.5. Spider web sign
The “spider web sign” was defined by Wu and colleagues [14], and they described it as an angular or triangular-shaped peripheral GGO with interstitial thickening like a spider web in a corner, but its pathophysiology has not been clearly revealed. They reported that the reversed halo sign was detected in 20 of 80 patients (25%) with COVID-19 pneumonia [14]. Moreover, Li et al. [30] detected the spider web sign in 21 of 83 (25.3%) patients with COVID-19 pneumonia. Apart from these 2 studies, there are no other studies in the literature describing or investigating the “spider web sign”. Therefore, this finding

Figure 6. A 40-year-old female patient was presented with complaints of fever that had been ongoing for 5 days, and newly emerged severe dyspnoea. The patient’s D-dimer level was found to be very high and contrast-enhanced pulmonary CT angiography was obtained. a) Axial CT image at the level of the origin of the middle lobe bronchus with mediastinum window settings shows bilateral diffuse pulmonary embolism (red arrows), bilateral mild pleural effusion, and subpleural triangular-shaped opacity with a reverse halo sign in the left lung compatible with pulmonary infarction (red frame). b, c) Axial CT images of the same patient with lung window settings show multiple subpleural consolidation and ground-glass opacity areas (red frames). The nasopharyngeal swab test of the patient was positive for 2019-nCoV.
needs to be investigated in patients with non-COVID-19 pneumonia and COVID-19 pneumonia.

3.6. Lymphadenopathy

Mediastinal lymphadenopathy has been infrequently reported in COVID-19 patients, and lymphadenopathy has been shown as a risk factor for severe and progressive COVID-19 pneumonia [14,31,37]. In the literature, the frequency of mediastinal lymphadenopathy has been reported between 0% and 29% in patients with COVID-19 [11,13,14,18–38]. Lymphadenopathy is a rare finding in viral pneumonia, and the detection of pleural effusion, lung nodules with a tree-in-bud pattern, and ill-defined micronodules may suggest bacterial superinfection [31–34].

3.7. Pericardial effusion

Pericardial effusion has been rarely reported in COVID-19 patients, which may indicate the occurrence of myocardial and/or pericardial inflammation [14,18,23,30]. Li et al. [30] have reported that COVID-19 patients with severe and critical diseases showed a higher frequency of pericardial effusion than noncritical patients. Recently, Xu et al. [23] found the pericardial effusion in 1 of 90 (1.1%) patients with COVID-19.

Table 2. The reported prevalence of the unusual computed tomography findings.

| Publication       | Number of patients | Study Origin | Pleural thickening and/or effusion | Air bubble sign | Nodules | Reversed halo sign | Spider web sign | LAP | Pericardial effusion |
|-------------------|--------------------|--------------|-----------------------------------|----------------|---------|--------------------|----------------|-----|---------------------|
| Chung et al. [11] | 21                 | China        | 0 (0%)                            | 0 (0%)         | -       | -                  | -              | 0   | 0 (0%)              |
| Bernheim et al. [13] | 121               | U.S.A.       | 1 (0.8%)                          | 0 (0%)         | 2 (1.7%)| -                  | 0 (0%)         |     |                    |
| Wu et al. [14]    | 80                 | China        | 5 (6%)                            | 10 (12.5%)     | -       | -                  | 20 (25%)       | 3   | 4 (5%)              |
| Song et al. [18]  | 51                 | China        | 4 (8%)                            | 3 (6%)         | 3 (6%)  | -                  | -              |     |                    |
| Pan et al. [19]   | 63                 | China        | 8 (12.7%)                         | -              | 2 (3.6%)| 1 (1%)            | 1 (1%)         |     |                    |
| Ng et al. [20]    | 21                 | China        | 0 (0%)                            | 1 (4.8%)       | 2 (9.6%)| 0 (0%)            | 0 (0%)         |     |                    |
| Pan et al. [21]   | 21                 | China        | -                                 | -              | -       | -                  | -              |     |                    |
| Han et al. [22]   | 108                | China        | 0 (0%)                            | -              | -       | -                  | 0 (0%)         | 9   | 0 (0%)              |
| Xu et al. [23]    | 90                 | China        | 4 (4%)                            | -              | -       | -                  | 1 (1%)         | 1   | 1 (1%)              |
| Zhao et al. [24]  | 101                | China        | 14 (13.9%)                        | 23 (22.8%)     | -       | -                  | 1 (1%)         |     |                    |
| Zhou et al. [25]  | 62                 | China        | 6 (9.7%)                          | 34 (54.8%)     | -       | -                  | -              | 0   | 0 (0%)              |
| Xu et al. [26]    | 41                 | China        | 2 (7.1%)                          | -              | -       | -                  | 1 (3.6%)       |     |                    |
| Li et al. [27]    | 51                 | China        | 1 (2.0%)                          | 11 (21.6%)     | 2 (3.9%)| 0 (0%)            | -              |     |                    |
| Yang et al. [28]  | 149                | China        | 10 (6.7%)                         | 12 (8.1%)      | 3 (2%)  | -                  | 7 (4.7%)       |     |                    |
| Ai et al. [29]    | 888                | China        | -                                 | 24 (3%)        | -       | -                  | -              |     |                    |
| Li et al. [30]    | 83                 | China        | 7 (8.4%)                          | 6 (7.2%)       | 21 (25.3%)| 7 (8.4%)       | 4 (4.8%)       |     |                    |
| Xiong et al. [31] | 42                 | China        | 5 (12%)                           | -              | -       | -                  | 12 (29%)       | 0   | 0 (0%)              |
| Bai et al. [32]   | 219                | China        | 32 (15%)                          | 70 (32%)       | 11 (5%) | -                  | 6 (3%)         |     |                    |
| Cheng et al. [33] | 11                 | China        | 0 (0%)                            | 1 (9.1)        | 3 (27.3)| -                  | 0 (0%)         |     |                    |
| Shi et al. [34]   | 81                 | China        | 4 (5%)                            | 8 (10%)        | 5 (6%)  | -                  | 5 (6%)         |     |                    |
| Wang et al. [35]  | 93                 | China        | 8 (8.6%)                          | 12 (12.9%)     | 17 (18.3%)| 14 (15.1%)| 6 (6.5%)       |     |                    |
| Fan et al. [36]   | 150                | China        | 6 (4%)                            | 18 (12%)       | -       | -                  | 2 (1.3%)       |     |                    |
| Colombi et al. [37]| 236               | Italy        | 47 (20%)                          | -              | -       | -                  | 57 (24%)       |     |                    |
| Zhang et al. [38] | 120                | China        | 9 (8%)                            | 65 (54%)       | -       | -                  | 5 (4%)         |     |                    |
| Zhu et al. [39]   | 72                 | China        | 3 (6.8)                           | 36 (50%)       | -       | -                  | -              |     |                    |
| Wang et al. [40]  | 110                | China        | 1 (0.9%)                          | -              | -       | -                  | -              |     |                    |
| Li et al. [41]    | 56                 | China        | 5 (8.9%)                          | 0 (0%)         | -       | -                  | 0 (0%)         |     |                    |
| Guan et al. [42]  | 47                 | China        | 0 (0%)                            | 1 (2.1%)       | -       | -                  | 0 (0%)         |     |                    |
| Liu et al. [43]   | 67                 | China        | 3 (4.5%)                          | -              | -       | -                  | -              |     |                    |

LAP; lymphadenopathy.
**Figure 7.** A 56-year-old man with COVID-19. Axial chest CT image with lung window settings shows bilateral focal ground-glass opacities in both lungs (a, red frame). Chest CT image with mediastinum window settings shows focal pleural thickening in the left lower lobe, near the focal ground-glass opacity (b, arrowheads).

**Figure 8.** A 75-year-old symptomatic man with COVID-19. Axial chest CT image shows mixed opacity (ground-glass opacity with consolidation) area in the right middle lobe (red frame), and that includes cystic air space (air bubble, red arrow).
patients with COVID-19 pneumonia. However, elderly patients, and especially those with additional heart failure, may have pericardial effusion independent of COVID-19.

4. Structured CT reporting for assessment of COVID-19

Although chest CT findings in COVID-19 patients can partially overlap with other diseases, especially other types of viral infections, COVID-19 may have characteristic CT features that are less common in other diseases [32]. Various recommendations have been published to standardize the structured CT reporting for the suspected COVID-19. The first of these is the Radiological Society of North America (RSNA) expert consensus statement, which suggests a standardized reporting and a classification of imaging features for COVID-19 pneumonia (i.e. negative for typical appearance, vague appearance, atypical appearance, and pneumonia) [49]. Salehi and colleagues [50] have defined a new classification by analysing 37 published studies that examined the diagnostic chest CT findings of COVID-19 patients. There are 5 categories in this classification: COVID-RADS 0; normal CT findings, COVID-RADS 1; atypical CT findings (inconsistent with COVID-19), COVID-RADS 2A; fairly typical findings, COVID-RADS 2B; combination of atypical findings with typical/fairly typical findings, and COVID-RADS 3; typical CT findings [50] (Table 3). However, the groups in this classification are based on the results obtained from a systematic review, and clinical success and applicability of this classification are unknown. Recently, the Dutch Radiological Society defined a new classification (CO-RADS) for pulmonary involvement in cases presenting with moderate to severe symptoms of COVID-19 [51]. In this standardized assessment (CO-RADS), a substantial agreement was found among 8 observers (Fleiss’ kappa of 0.47, 95% CI 0.45–0.49) and the discriminatory power of the CO-RADS for diagnosing COVID-19 was high (with an area under the curve value of 0.91, 95% CI 0.85–0.97). Therefore, the authors stated that CO-RADS is very suitable for use in clinical practice [51] (Table 4).

5. The severity of pulmonary involvement on CT

The visual (semiquantitative) evaluation of disease severity on chest CT can reflect the clinical classification (mild, common, severe, or critical disease) and prognosis of patients with COVID-19 pneumonia [11,30,41]. Therefore, the staging of lung involvement has been defined in COVID-19 patients. In these staging methods, the percentage of each lung lobe involvement is assessed.
and the portion of the total lung involvement is calculated semiquantitatively (visually). For example, Chung et al. [11] and Li et al. [41] used the same scoring as follows: none (0%); a score of 0, minimal (1%–25%); a score of 1, mild (26%–50%); a score of 2, moderate (51%–75%); a score of 3, and severe (76%–100%); a score of 4. An overall lung involvement score was reached by summing the 5 lobe scores (0–20). Besides, quantitative CT assessment methods and artificial intelligence applications can be successfully applied in the diagnosis of COVID-19 and in the evaluation of disease severity [37,52,53].

6. Radiation concern
Exposure to medical radiation is a concern in patients with suspected or diagnosed COVID-19 pneumonia, especially in infants, children, young adults, and pregnant patients. Therefore, it is necessary to prevent or reduce radiation exposure [6,7,20,54]. First, it should be distinguished appropriately in which patients need imaging and in which patient imaging is not needed. In cases with COVID-19 suspicion, imaging methods should be avoided if clinical follow-up and management will not change. In a multinational recommendation that is newly defined and widely used by Fleischner Society, imaging is not recommended for cases with suspected of COVID-19 without risk factors (such as diabetes, older age, chronic obstructive pulmonary disease) and mild clinical findings. Moreover, imaging methods are indicated in a COVID-19 patient whose respiratory condition has worsened [6]. Second, chest CT should be obtained as low as possible radiation dose in cases with CT indication. Dangis et al. [54] showed that chest CT with low-dose settings would provide the diagnosis of COVID-19 pneumonia with similar accuracy as standard-dose chest CT.

7. Contamination of radiology units
Radiography machines and CT scanners are frequently used in patients with suspected COVID-19 during the pandemic. Therefore, vital precautions should be provided for COVID-19 in radiology units [6,55]. First, ensuring the health of radiology workers is essential for the best care of patients. For this reason, staff working in radiology units should use necessary personal protective equipment according to their contact with the patient. Besides, all

Figure 10. A 58-year-old man with COVID-19. Axial chest CT image with lung window settings shows bilateral multifocal ground-glass opacities in both lungs. The ground-glass opacity in the left lower lobe surrounded by denser ring-like (crescentic shape) consolidation, which is compatible with a reversed halo sign (arrowheads).
patients with a suspicion for COVID-19 who presented to the radiology unit should use a standard surgical mask. Second, contamination of radiography machines and CT scanners are a major concern. Therefore, it is necessary to use a dedicated radiography machine and CT device in patients with suspicion for COVID-19 to reduce the risk of disease transmission. Also, these dedicated devices should never be used in patients without suspicion for COVID-19. Third, to reduce the risk of contamination, the CT scanners and radiography devices and rooms must be deeply cleaned and disinfected according to standard protocols after each exam. If patient masking is available, active (mechanically) air exchange procedures are not required [6,55]. After each imaging procedure, the room

| CT findings                                  | Description                                                   | COVID-RADS grade | Level of suspicion |
|----------------------------------------------|----------------------------------------------------------------|------------------|--------------------|
| Normal chest CT                              |                                                                | 0                | Low                |
| Atypical findings                            | - Pleural effusion                                            |                  |                    |
| (Inconsistent with COVID-19)                 |                                                                |                  |                    |
|                                              | - Cavity                                                      |                  |                    |
|                                              | - Pulmonary nodule(s)                                         |                  |                    |
|                                              | - Nodular pattern                                             |                  |                    |
|                                              | - Lymphadenopathy                                             |                  |                    |
|                                              | - Peribronchovascular distribution                           |                  |                    |
|                                              | - Halo sign                                                   | 1                | Low                |
|                                              | - Tree-in-bud sign                                            |                  |                    |
|                                              | - Bronchiectasis                                              |                  |                    |
|                                              | - Airway secretions                                           |                  |                    |
|                                              | - Pulmonary emphysema                                         |                  |                    |
|                                              | - Pulmonary fibrosis                                          |                  |                    |
|                                              | - Isolated pleural thickening                                 |                  |                    |
|                                              | - Pneumothorax                                                |                  |                    |
|                                              | - Pericardial effusion                                        |                  |                    |
| Fairly typical findings                      | - Single GGO (early)                                          | 2A               | Moderate           |
|                                              | - Consolidation without GGO (late/complicated)                |                  |                    |
|                                              | - Focal pleural thickening                                    |                  |                    |
|                                              | - Vascular enlargement                                        |                  |                    |
|                                              | - Air bronchogram                                             |                  |                    |
|                                              | - Bronchial wall thickening                                   |                  |                    |
|                                              | - White lung stage (late/complicated)                         |                  |                    |
|                                              | - Parenchymal fibrotic bands (late/remission)                  |                  |                    |
| Combination of atypical findings with typical/fairly typical findings |                                                                | 2B               | Moderate           |
| Typical findings                             | - Multifocal GGO                                              | 3                | High               |
|                                              | - GGO with superimposed consolidation                         |                  |                    |
|                                              | - Consolidation predominant pattern (late/complicated)         |                  |                    |
|                                              | - Linear opacities (late/complicated)                         |                  |                    |
|                                              | - Crazy paving pattern (late/complicated)                     |                  |                    |
|                                              | - Melted sugar sign (late/remission)                          |                  |                    |

GGO, ground glass opacity.

Table 3. The proposed coronavirus disease 2019 (COVID-19) imaging reporting and data system (COVID-RADS) [50].
downtime for the decontamination of room and devices is approximately 30 min.

8. Conclusion
In conclusion, early diagnosis of COVID-19 is essential to prevent transmission and provide close clinical observation of the patients. While the gold standard for the diagnosis of COVID-19 is RT-PCR, CT should be obtained in a limited population (in COVID-19 patients who have worsening respiratory symptoms, in patients with moderate-severe clinical features of COVID-19, in medical triage of COVID-19 suspected cases with moderate-severe clinical features, and a high pretest probability of COVID-19 in the lack of personal protective equipment or availability of RT-PCR test) due to radiation concern. Although bilateral and peripheral GGO without or with superimposed interstitial thickening (crazy-paving pattern), and/or consolidation with the multi-lobar distribution is the common CT features in COVID-19, chest CT features can vary among patients. Moreover, chest CT is not just a diagnostic or screening method in cases with suspected COVID-19. In patients with COVID-19, chest CT is especially crucial in determining the severity of pneumonia, which has a prognostic impact [11,37,41].

Acknowledgements
Authors declare that there is no conflict of interest. No informed consent was received.

References
1. Zhu N, Zhang D, Wang W, Li X, Yang B et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine 2020; 382(8): 727-733. doi:10.1056/NEJMoa2001017
2. World Health Organization. Coronavirus Disease 2019 (COVID-19) Situation Report–96. Geneva, Switzerland: World Health Organization; 2020.
3. Xu Z, Shi L, Wang Y, Zhang J, Huang L et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respiratory Medicine 2020; 8(4): 420-422.
4. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S et al. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 2020; 201187. doi: 10.1148/radiol.2020201187 [Epub ahead of print]
5. Zhou F, Yu T, Du R, Fan G, Liu Y et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-1062.
6. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP et al. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner Society. Radiology 2020; 201365. doi:10.1148/radiol.2020201365 [Epub ahead of print]
7. China National Health Commission. Diagnosis and Treatment of Pneumonitis Caused by New Coronavirus (trial version 7). Pekin, China: China NHC; 2020.
8. World Health Organization. Country & Technical Guidance-Coronavirus Disease (COVID-19). Geneva, Switzerland: WHO; 2020.
9. Xie X, Zhong Z, Zhao W, Zheng C, Wang F et al. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology 2020; 200343. doi: 10.1148/radiol.2020200343 [Epub ahead of print]
10. Fang Y, Zhang H, Xie J, Lin M, Ying L et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology 2020; 200432. doi: 10.1148/radiol.2020200432 [Epub ahead of print]
11. Chung M, Bernheim A, Mei X, Zhang N, Huang M et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology 2020; 295(1): 202-207. doi: 10.1148/radiol.2020200230
12. Ufuk F. 3D CT of novel coronavirus (COVID-19) pneumonia. Radiology 2020; 21183. doi: 10.1148/radiol.202021183 [Epub ahead of print]
13. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology 2020; 200463. doi: 10.1148/radiol.2020200463 [Epub ahead of print]
14. Wu J, Wu X, Zeng W, Guo D, Fang Z et al. Chest CT findings in patients with corona virus disease 2019 and its relationship with clinical features. Investigative Radiology 2020; 55(5): 257-261. doi: 10.1097/RLI.0000000000000670
15. Huang P, Liu T, Huang L, Liu H, Lei M et al. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Radiology 2020; 295(1): 22-23. doi: 10.1148/radiol.2020200330
16. Yang W, Sirajuddin A, Zhang X, Liu G, Teng Z et al. The role of imaging in 2019 novel coronavirus pneumonia (COVID-19), European Radiology 2020. doi: 10.1007/s00330-020-06827-4 [Epub ahead of print]
17. Hansell DM, Bankier AA, MacMahon H, McCloud TC, Muller NL et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008; 246: 697-722.
18. Song F, Shi N, Shan F, Zhang Z, Shen J et al. Emerging 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology 2020; 295(1): 210-217.
19. Pan Y, Guan H, Zhou S. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. European Radiology 2020. doi: 10.1007/s00330-020-06731-x [Epub ahead of print]
20. Ng M, Lee EYP, Yang J, Yang F, Li X et al. Imaging profile of the COVID-19 infection: radiologic findings and literature review. Radiology: Cardiothoracic Imaging 2020; 2(1): e200034. doi: 10.1148/rtct.2020200034
21. Pan F, Ye T, Sun P, Gui S, Liang B et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology 2020; 200370. doi: 10.1148/radiol.2020200370 [Epub ahead of print]
22. Han R, Huang L, Jiang H, Dong J, Peng H et al. Early clinical and CT manifestations of coronavirus disease 2019 (COVID-19) pneumonia. AJR American Journal of Roentgenology 2020; 1-6. doi: 10.2214/AJR.20.22961 [Epub ahead of print]
23. Xu X, Yu C, Qu J, Zhang L, Jiang S et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. European Journal of Nuclear Medicine and Molecular Imaging 2020; 47(5): 1275-1280.
24. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study. AJR American Journal of Roentgenology 2020; 214(5): 1072-1077.
25. Zhou S, Wang Y, Zhu T, Xia L. CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China. AJR American Journal of Roentgenology 2020; 1-8. doi: 10.2214/AJR.20.22975 [Epub ahead of print]
26. Xu YH, Dong JH, An WM, Ly XY, Yin XP et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. Journal of Infection 2020; 80(4): 394-400. doi: 10.1016/j.jinf.2020.02.017
27. Li Y, Xia L. Coronavirus disease 2019 (COVID-19): role of chest CT in diagnosis and management [published online ahead of print, 2020 March 4]. AJR American Journal of Roentgenology 2020; 1-7. doi:10.2214/AJR.20.22954
28. Yang W, Cao Q, Qin L, Wang X, Cheng Z et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. Journal of Infection 2020; 80(4): 388-393. doi:10.1016/j.jinf.2020.02.016
29. Ai T, Yang Z, Hou H, Zhan C, Chen C et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 Cases. Radiology 2020; 200642. doi:10.1148/radiol.2020200642 [Epub ahead of print]
30. Li K, Wu J, Wu F, Guo D, Chen L et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Investigative Radiology 2020; 10.1097/RLI.0000000000000672. doi:10.1097/RLI.0000000000000672 [Epub ahead of print]
31. Xiong Y, Sun D, Liu Y, Fan Y, Zhao L et al. Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes. Investigative Radiology 2020; 10.1097/RLI.0000000000000674 [Epub ahead of print]
32. Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology 2020. doi:10.1148/radiol.2020200823 [Epub ahead of print]
33. Cheng Z, Lu Y, Cao Q, Qin L, Pan Z et al. Clinical features and chest CT manifestations of coronavirus disease 2019 (COVID-19) in a single-center study in Shanghai, China. AJR American Journal of Roentgenology 2020; 1-6. doi:10.2214/AJR.20.22959 [Epub ahead of print]
34. Shi H, Han X, Jiang N, Cao Y, Alwalid O et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infectious Diseases 2020; 20(4): 425-434. doi:10.1016/S1473-3099(20)30086-4
35. Wang J, Xu Z, Wang J, Feng R, An Y et al. CT characteristics of patients infected with 2019 novel coronavirus: association with clinical type. Clinical Radiology 2020. doi:10.1016/j.crad.2020.04.001 [Epub ahead of print]
36. Fan N, Fan W, Li Z, Shi M, Liang Y. Imaging characteristics of initial chest computed tomography and clinical manifestations of patients with COVID-19 pneumonia. Japanese Journal of Radiology 2020. doi:10.1007/s11604-020-00973-x [Epub ahead of print]
37. Colombi D, Bodini FC, Petrini M, Matti G, Morelli N et al. Well-aerated lung on admitting chest CT to predict adverse outcome in COVID-19. Radiology 2020. doi:10.1148/radiol.2020201433 [Epub ahead of print]

38. Zhang R, Ouyang H, Fu L, Wang S, Han J et al. CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan City. European Radiology 2020. doi:10.1007/s00330-020-06854-1 [Epub ahead of print]

39. Zhu T, Wang Y, Zhou S, Zhang N, Xia L. A comparative study of chest computed tomography factors in young and older adults with coronavirus disease (COVID-19). Journal of Thoracic Imaging 2020. doi:10.1097/RTI.0000000000000513 [Epub ahead of print]

40. Wang K, Kang S, Tian R, Zhang X, Zhang X et al. Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area. Clinical Radiology 2020; 75(5): 341-347. doi:10.1016/j.crad.2020.03.004

41. Li K, Fang Y, Li W, Pan C, Qin P et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). European Radiology 2020. doi:10.1007/s00330-020-06817-6 [Epub ahead of print]

42. Guan CS, Lv ZB, Yan S, Du YN, Chen H et al. Imaging features of coronavirus disease 2019 (COVID-19) on thin-section CT. Academic Radiology 2020; 27(5): 609-613. doi:10.1016/j.acra.2020.03.002

43. Liu KC, Xu P, Lv WF, Qiu XH, Yao JL et al. CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity. European Journal of Radiology 2020; 126: 108941. doi:10.1016/j.ejrad.2020.108941

44. Grillot F, Behr J, Calame P, Aubry S, Delabrousse E. Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography. Radiology 2020; 201544. doi:10.1148/radiol.2020201544 [Epub ahead of print]

45. Oudkerk M, Büller HR, Kuipers D, van Es N, Oudkerk SF et al. Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the National Institute for Public Health of the Netherlands. Radiology. 2020. doi:10.1148/radiol.2020201629 [Epub ahead of print]

46. Ajlaj AM, Ahyad RA, Jamjoom LG, Alharthy A, Madani TA. Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings. AJR American Journal of Roentgenology 2014; 203(4): 782-787. doi: 10.2214/AJR.14.13021

47. Leonard-Lorant I, Delabranche X, Severac F, Helms J, Pauzet C et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-Dimer levels. Radiology 2020. doi:10.1148/radiol.2020201561 [Epub ahead of print]

48. Rodrigues JCL, Hare SS, Edey A, Devaraj A, Jacob J et al. An update on COVID-19 for the radiologist - a British society of Thoracic imaging statement. Clinical Radiology 2020; 75(5): 323-325. doi:10.1016/j.crad.2020.03.003

49. Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH et al. Radiological society of north America Expert Consensus Statement on reporting chest CT findings related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American college of Radiology, and RSNA. Radiology: Cardiothoracic Imaging 2020; 2(2): e200152.

50. Salehi S, Abedi A, Balakrishnan S, Gholamrezaeezhad A. Coronavirus disease 2019 (COVID-19) imaging reporting and data system (COVID-RADS) and common lexicon: a proposal based on the imaging data of 37 studies. European Radiology 2020. doi:10.1007/s00330-020-06863-0 [Epub ahead of print]

51. Prokop M, van Everdingen W, van Rees Vellinga T, Quares van Ufford J, Stöger I et al. CO-RADS - A categorical CT assessment scheme for patients with suspected COVID-19: definition and evaluation. Radiology 2020; 201473. doi:10.1148/radiol.2020201473 [Epub ahead of print]

52. Qi X, Lei J, Yu Q, Xi Y, Wang Y et al. CT imaging of coronavirus disease 2019 (COVID-19): from the qualitative to quantitative. Annals of Translational Medicine 2020; 8(5): 256. doi:10.21037/atm.2020.02.91

53. Bai HX, Wang R, Xiong Z, Hsieh B, Chang K et al. AI augmentation of radiologist performance in distinguishing COVID-19 from pneumonia of other etiology on chest CT. Radiology 2020. doi:10.1148/radiol.2020201491 [Epub ahead of print]

54. Dangis A, Gieraerts C, De Bruecker Y, Janssen L, Valgaeren H et al. Accuracy and reproducibility of low-dose submillisievert chest CT for the diagnosis of COVID-19. Radiology: Cardiothoracic Imaging 2020; 2(2). doi: 10.1148/ryct.2020200196 [Epub ahead of print]

55. Mossa-Basha M, Meltzer CC, Kim DC, Tuite MJ, Kolli KP et al. Radiology Department Preparedness for COVID-19: Radiology Scientific Expert Panel. Radiology 2020; 200988. doi: 10.1148/radiol.2020200988 [Epub ahead of print]